Alvotech (ALVO)

Market Cap	3.53B
Revenue (ttm)	93.38M
Net Income (ttm)	-551.73M
Shares Out	266.82M
EPS (ttm)	-2.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,686,501
Open	13.05
Previous Close	12.89
Day's Range	12.75 - 14.00
52-Week Range	6.70 - 18.00
Beta	0.07
Analysts	Buy
Price Target	15.00 (+13.46%)
Earnings Date	May 16, 2024

About ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 1,026
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVO

Financial Performance

In 2023, Alvotech's revenue was $93.38 million, an increase of 9.84% compared to the previous year's $85.02 million. Losses were -$551.73 million, 7.43% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price forecast is $15.0, which is an increase of 13.46% from the latest price.

Price Target

$15.0

(13.46% upside)

Analyst Consensus: Buy